Associated tags: Inflammation, GRI, NKT, IPF, NK, Fibrosis, Natural killer T cell, Doctor of Philosophy, Pharmaceutical industry, Patient
Locations: PHILADELPHIA, PENNSYLVANIA, PA, UK, CALIFORNIA, LA JOLLA, US, CA, UNITED KINGDOM, LA, NEW YORK CITY, NY
LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.
Key Points:
- LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE!
- with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.
Natural killer T cell,
IP,
IPF,
KIPO,
GRI,
Doctor of Philosophy,
Idiopathic disease,
NKT,
RAR,
Patent,
Retinoic acid,
Oxygen,
Liver,
Patient,
Treatment,
Movement,
Idiopathic pulmonary fibrosis,
Interim,
Pharmaceutical industry LA JOLLA, CA, April 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions."
Key Points:
- The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver.
- “We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators.
- Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases.
- For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.
Key Points:
- LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.
- Details of the presentation are as follows:
Research,
Conference,
Lupus,
Inflammation,
Patient,
Food and Drug Administration,
CTA,
Doctor of Philosophy,
SLE,
Insurance,
GRI,
IPF,
Fibrosis,
Oxygen,
Immune system,
Injury,
NKT,
Food,
Movement,
Lupus nephritis,
Autoimmune disease,
Natural killer T cell,
Medication,
Pharmaceutical industry LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.
Key Points:
- IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
- GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells.
- Research and development expenses were $3.2 million and $0.2 million for the years ended December 31, 2023 and 2022, respectively.
- General and administrative expenses were $8.2 million and $2.0 million for the years ended December 31, 2023 and 2022, respectively.
LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.
Key Points:
- LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.
- In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- For more information about the conference, please visit the conference website .
Retinoic acid,
Patient,
CIPO,
Doctor of Philosophy,
Idiopathic pulmonary fibrosis,
GRI,
IPF,
RAR,
Treatment,
Oxygen,
Patent,
Interim,
NKT,
Idiopathic disease,
Liver,
Movement,
Natural killer T cell,
Pharmaceutical industry LA JOLLA, CA, March 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, "Prevention and Treatment of Inflammatory Conditions." A patent from the recently allowed application is expected to be issued in the coming months.
Key Points:
- A patent from the recently allowed application is expected to be issued in the coming months.
- “We have remained committed to bolstering our intellectual property protection across our innovative pipeline of NKT cell modulators.
- IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
- For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .
Oxygen,
IPF,
Idiopathic disease,
Serum,
Doctor of Philosophy,
Blood,
Homeostasis,
Idiopathic pulmonary fibrosis,
Inflammation,
Vital signs,
Safety,
Health care,
BAL,
Biomarker,
Pharmacokinetics,
Patient,
NKT,
Natural killer T cell,
Bronchoalveolar lavage,
NIHR,
Movement,
GRI,
CTA,
Immune system,
Pharmaceutical industry LA JOLLA, CA, March 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.
Key Points:
- The MHRA is the UK regulatory authority, a government agency, for medicines and medical devices.
- The MHRA is responsible for the regulation of medicines and medical devices and equipment used in healthcare and the investigation of harmful incidents.
- “We are pleased to receive authorization from the MHRA and take a step in the global expansion of our clinical development for GRI-0621.
- We are focused on driving this program forward and generating important data readouts this year,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
Security (finance),
GRI,
Offering,
Form S-1,
Madison Avenue,
Telephone,
Prospectus,
Sale,
Series,
Natural killer T cell,
Form The closing of the Offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.
Key Points:
- The closing of the Offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the Offering are expected to be approximately $5.5 million.
- The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes.
- The Offering is being made only by means of a prospectus forming part of the effective registration statement.
LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-7 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 19, 2024. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on January 29, 2023. The Company’s common stock will open for trading under a new CUSIP number 3622AW 205 on The Nasdaq Capital Market on January 30, 2024, on a split-adjusted basis under the current ticker symbol “GRI.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Key Points:
- GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024
LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-7 reverse stock split (the “Reverse Split”) of the Company’s common stock.
- The 1-for-7 Reverse Split will automatically convert every 7 current shares of the Company’s common stock into one share of common stock.
- Stockholders who would otherwise hold a fractional share of the Company’s common stock following the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the reverse stock split, on January 29, 2024.
- Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split.
Retrieved on:
Tuesday, December 5, 2023
BAL,
Movement,
Natural killer T cell,
Bronchoalveolar lavage,
IPF,
Blood,
Doctor of Philosophy,
Pharmacokinetics,
Serum,
Oxygen,
Biomarker,
Interim,
GRI,
Safety,
Vital signs,
NKT LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. Patient dosing is expected imminently. Interim data from the Phase 2a biomarker study is expected in the first half of 2024 and topline results are expected in the second half of 2024.
Key Points:
- Interim data from the Phase 2a biomarker study is expected in the first half of 2024 and topline results are expected in the second half of 2024.
- IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
- “The start of enrollment marks another important step forward for GRI as we continue to execute our clinical development plans for our lead program, GRI-0621.
- We are pleased to meet this significant milestone and remain focused on the successful execution of this Phase 2a study.
